N-(1-(5-chloro-8-hydroxyquinolin-7-yl)ethyl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(1-(5-chloro-8-hydroxyquinolin-7-yl)ethyl)acetamide
• 英文别名: N-[1-(5-chloro-8-hydroxyquinolin-7-yl)ethyl]acetamide
• 化学式: C₁₃H₁₃ClN₂O₂
• 分子量: 264.711
• InChiKey: VXTBFUPMJZNGSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(1-(8-(benzyloxy)-5-chloroquinolin-7-yl)ethyl)acetamide 在 三氯化硼 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以86%的产率得到N-(1-(5-chloro-8-hydroxyquinolin-7-yl)ethyl)acetamide
  参考文献：
  名称：

  WO2008/14602

  摘要：

  公开号：

文献信息

• Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12- Lipoxygenase
  作者：Victor Kenyon、Ganesha Rai、Ajit Jadhav、Lena Schultz、Michelle Armstrong、J. Brian Jameson、Steven Perry、Netra Joshi、James M. Bougie、William Leister、David A. Taylor-Fishwick、Jerry L. Nadler、Michael Holinstat、Anton Simeonov、David J. Maloney、Theodore R. Holman

  DOI：10.1021/jm2005089

  日期：2011.8.11

  We report the discovery of novel small molecule inhibitors of platelet-type 12-human lipoxygenase, which display nanomolar activity against the purified enzyme, using a quantitative high-throughput screen (qHTS) on a library of 153607 compounds. These compounds also exhibit excellent specificity, >50-fold selectivity vs the paralogues, 5-human lipoxygenase, reticulocyte 15-human lipoxygenase type-1, and epithelial 15-human lipoxygenase type-2, and >100-fold selectivity vs ovine cyclooxygenase-1 and human cyclooxygenase-2. Kinetic experiments indicate this chemotype is a noncompetitive inhibitor that does not reduce the active site iron. Moreover, chiral HPLC separation of two of the racemic lead molecules revealed a strong preference for the (-)-enantiomers (IC50 of 0.43 +/- 0.04 and 0.38 +/- 0.05 mu M) compared to the (+)-enantiomers (IC50 of >25 mu M for both), indicating a fine degree of selectivity in the active site due to chiral geometry. In addition, these compounds demonstrate efficacy in cellular models, which underscores their relevance to disease modification.
• QUINOLINE DERIVATIVES
  申请人：Envivo Pharmaceuticals, Inc.

  公开号：EP2079699A1

  公开（公告）日：2009-07-22
• [EN] QUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOLINE
  申请人：CHRONOGEN INC

  公开号：WO2008014602A1

  公开（公告）日：2008-02-07

  [EN] The invention relates to new quinoline derivatives which are active CLK-1 inhibitors. More specifically, the CLK-1 inhibitors of the invention are compounds of formula (A). The invention also relates to pharmaceutical compositions comprising such compounds and to methods for the prophylaxis and/or treatment of disorders or their associated symptoms for which the inhibition of CLK-1 is beneficial.
  [FR] L'invention concerne de nouveaux dérivés de quinoline constituant des inhibiteurs actifs de CLK-1. Les inhibiteurs de CLK-1 de l'invention sont, plus spécifiquement, des composés représentés par la formule (A). L'invention concerne également des compositions pharmaceutiques contenant lesdits composés et des méthodes prophylactiques et/ou thérapeutiques de troubles ou des symptômes associés dans lesquels l'inhibition de CLK-1 est bénéfique.
• WO2008/14602
  申请人：——

  公开号：——

  公开（公告）日：——